检索结果-南通市图书馆

Colorectal cancer screening: Comparison of transferrin and immuno fecal occult blood test

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2012年第21期18卷 2682-2688页

作者： Ji-Gui Chen Juan Cai Huan-Lei Wu Hua Xu Yu-Xing Zhang Chao Chen Qian Wang Jun Xu xiang-lin yuan Department of Anorectal Surgery the Eighth Hospital Wu-han 430030 Hubei Province China Department of On-cology Tongji Hospital Tongji Medical College HuazhongUniversity of Science and Technology Wuhan 430030 HubeiProvince China Department of Surgery Tongji Hospital Tongji Medi-cal College Huazhong University of Science and TechnologyWuhan 430030 Hubei Province China

AIM: To evaluate the sensitivity and specificity of transfesrrin dipstick test (Tf) in colorectal cancer (CRC) screening and precancerous lesions screening. METHODS: Eight hundreds and sixty-one individuals at high-risk for CRC were recruited. Six hundreds and eleven subsequently received the three fecal occult blood tests and colonoscopy with biopsy performed as needed. Fecal samples were obtained on the day before colonoscopy. Tf, immuno fecal occult blood test (IFOBT) and guaiac fecal occult blood test (g-FOBT) were performed simultaneously on the same stool. To minimize false-negative cases, all subjects with negative samples were asked to provide an additional stool specimen for a second test even a third test. If the results were all negative after testing three repeated samples, the subject was considered a true negative. The performance characteristics of Tf for detecting CRC and precancerous lesions were examined and compared to those of IFOBT and the combination of Tf, IFOBT and g-FOBT. RESULTS: A total of six hundreds and eleven subjects met the study criteria including 25 with CRC and 60 with precancerous lesions. Sensitivity for detecting CRC was 92% for Tf and 96% for IFOBT, specificities of Tf and IFOBT were both 72.0% (95% CI: 68.2%-75.5%; χ2 = 0.4, P > 0.05); positive likelihood ratios of those were 3.3 (95% CI: 2.8-3.9) and 3.4 (95% CI: 2.9-4.0), respectively. In precancerous lesions, sensitivities for Tf and IFOBT were 50% and 58%, respectively (χ 2 = 0.8, P > 0.05); specificities of Tf and IFOBT were 71.5% (95% CI: 67.6%-75.1%) and 72.2% (95% CI: 68.4%-75.8%); positive likelihood ratios of those were 1.8 (95% CI: 1.3-2.3) and 2.1 (95% CI: 1.6-2.7), respectively; compared to IFOBT, g-FOBT+ Tf+ IFOBT had a significantly higher positive rate for precancerous lesions (83% vs 58%, respectively; χ 2 = 9.1, P 0.05); specificities of

关键词： Transferrin Immuno fecal occult blood test Colorectal cancer Precancerous lesions Transferrin dipstick test

Genetic Variants in CHEK1 Gene Are Associated with the Prognosis of Thoracic Esophageal Squamous Cell Carcinoma Patients Treated with Radical Resection

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Huazhong University of Science and Technology(Medical Sciences) 2016年第6期36卷 828-833页

作者： Jing LI Vang TANG Liu HUANG Qian-qian YU Guang-yuan HU Chao CHEN Peng ZHANG xiang-lin yuan Department of Oncology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430030 China Department of Orthopedics Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan430022 China

CHEK1 gene is known to play an important role in tumor progression by cell cycle ***,the association between CHEK1 and the prognosis of esophageal squamous cell carcinoma（ESCC） is *** this study,we explored the association between genetic variants in CHEK1 gene and prognosis of ESCC patients treated with radical resection.A total of 131 thoracic ESCC patients who underwent radical resection were included in this retrospective study and genotyped using the Mass Array *** to the univariate Cox hazard analysis,the GT/TT genotype of CHEK1 rs555752 was shown to be strongly related to a decreased overall survival（OS）（HR=2.560,95% CI：1.415–4.631,P=0.002） and disease-free survival（DFS）（HR=2.160,95% CI：1.258–3.710,P=0.005）.Furthermore,according to the multivariate Cox hazard analysis and multiple testing,patients with the GT/TT genotype of CHEK1 rs555752 had a notably decreased OS（HR=2.735,95% CI：1.468–5.096,P=0.002,Pc=0.006） and DFS（HR=2.282,95% CI：1.292–4.023,P=0.004,Pc=0.012）.In conclusion,genetic variants of the CHEK1 gene are significantly related to OS and DFS of ESCC patients,and may therefore be predictors of the prognosis of thoracic ESCC after surgery.

关键词： esophageal squamous cell carcinoma CHEKI single nucleotide polymorphism prognostic factor overall survival disease-free survival

Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第16期22卷 4250-4258页

作者： Qian-Qian Yu Hong Qiu Ming-Sheng Zhang Guang-yuan Hu Bo Liu Liu Huang Xin Liao Qian-Xia Li Zhi-Huan Li xiang-lin yuan Department of Oncology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Department of Geriatrics Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Department of Genetics and Complex Diseases Harvard T.H. Chan School of Public Health

AIM: To examine the predictive effects of baseline serum bilirubin levels and UDP-glucuronosyltransferase(UGT) 1A1*28 polymorphism on response of colorectal cancer to irinotecan-based ***: The present study was based on a prospective multicenter longitudinal trial of Chinese metastatic colorectal cancer(m CRC) patients treated with irinotecan-based chemotherapy(NCT01282658). Baseline serum bilirubin levels, including total bilirubin(TBil) and unconjugated bilirubin(UBil), were measured,and genotyping of UGT1A1*28 polymorphism was performed. Receiver operating characteristic curve(ROC) analysis was used to determine cutoff values of TBil and UBil. The TBil values were categorized into > 13.0 or ≤ 13.0 groups; the UBil values were categorized into > 4.1 or ≤ 4.1 groups. Combining the cutoff values of TBil and UBil, which was recorded as Co Bil, patients were classified into three groups. The classifier's performance of UGT1A1*28 and Co Bil for predicting treatment response was evaluated by ROC analysis. Associations between response and Co Bil or UGT1A1*28 polymorphism were estimated using simple and multiple logistic regression models. RESULTS: Among the 120 m CRC patients, the serum bilirubin level was significantly different between the UGT1A1*28 wild-type and mutant genotypes. Patients with the mutant genotype had an increased likelihood of a higher TBil(P = 0.018) and a higher UBil(P = 0.014) level compared with the wild-type genotype. Patients were stratified into three groups based on Co Bil. Group 1 was patients with TBil > 13.0 and UBil > 4.1; Group 2 was patients with TBil ≤ 13.0 and UBil > 4.1; and Group 3 was patients with TBil ≤ 13.0 and UBil ≤ 4.1. Patients in Group 3 had more than a 10-fold higher likelihood of having a response in the simple(OR = 11.250; 95%CI: 2.286-55.367; P = 0.003) and multiple(OR = 16.001; 95%CI: 2.802-91.371; P = 0.002) analyses compared with the Group 1 individuals. Patients carrying the UGT1A1*28(TA)7 allele we

关键词： Bilirubin Irinotecan Metastatic colorectal cancer Response UGT1A1*28

Mainchain conformation ordering self-assembly tailored room temperature phosphorescence emission

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Science China Chemistry 2025年第1期68卷 329-336页

作者： Yuzhu Li Yumeng Gao Feng Tian Yu Wang yuan Yao Shaoliang lin xiang Ma Binbin Xu Shanghai Key Laboratory of Advanced Polymeric Materials Key Laboratory for Ultrafine Materials of Ministry of Education School of Materials Science and Engineering East China University of Science and Technology Shanghai Synchrotron Radiation Facility Shanghai Advanced Research Institute Chinese Academy of Sciences Key Laboratory for Advance Materials and Feringa Noble Prize Scientist Joint Research Centre Frontiers Science for Materiobiology and Dynamic Chemistry School of Chemistry and Molecular Engineering East China University of Science & Technology

Developing organic room-temperature phosphorescence （RTP） materials with a wide range of tunable-emission is significant in expanding the applications of RTP ***,we rationally designed amphiphilic alternating copolymers poly(1,2-bis（4-alkoxyphenyl）ethane-1,2-dione-alt-（ethylene glycol）x)(P（Bz-alt-EGx）) that combined the advantage of alternating benzil and EGxskeleton,and tunable mainchain *** a mainchain conformation ordering assembly （COA） process,P（Bz-alt-EGx） self-assembled into well-defined platelets,and such assemblies emitted blue RTP at ca.425 nm due to the ordered folded-chain conformation and confined *** contrast,traditional self-assembly （TA） of P（Bz-alt-EGx） obtained less ordered aggregates,such as asymmetric worms,vesicles,and rod-like *** resultant less ordered aggregates exhibited yellow-green RTP at ca.550 *** wide-tuning RTP emission in solution （between blue and yellow-green,over125 nm） is realized using the P（Bz-alt-EGx） alternating copolymers under the treatment of different self-assembly *** study uncovers a new strategy to tailor the RTP emission through different self-assembly pathways and holds great promise for the fabrication of advanced optical materials.

关键词： self-assembly conformation ordering alternating copolymer phosphorescence emission

Expert consensus on maintenance treatment for metastatic colorectal cancer in China

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Cancer 2016年第1期35卷 20-25页

作者： Rui-Hua Xu lin Shen Jin Li Jian-Ming Xu Feng Bi Yi Ba Li Bai Yong-Qian Shu Tian-Shu Liu Yu-Hong Li Chun-Mei Bai xiang-lin yuan Jun Zhang Gong Chen Ai-Ping Zhou Ying yuan Xi-Jing Wang Xiao-Ping Qian Yan-Hong Deng Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center of Cancer Medicine Department of Medical Oncology Sun Yat-sen University Cancer Center Department of Gastrointestinal Medical Oncology Peking University Cancer Hospital Department of Oncology Tongji University Tianyou Hospital Department of Medical Oncology The 307th Hospital of Chinese People's Liberation Army Department of Medical Oncology West China Hospital of Sichuan University Department of Gastrointestinal Medical Oncology Tianjin Medical University Cancer Institute and Hospital Department of Medical Oncology The 301 th Hospital of Chinese People's Liberation Army Department of Medical Oncology Jiangsu Provincial Hospital Department of Medical Oncology Fudan University Zhongshan Hospital Department of Medical Oncology Peking Union Medical College Hospital Department of Medical Oncology Tongji Hospital of Tongji Medical CollegeHuazhong University of Science and Technology Department of Oncology Rui Jin HospitalShanghai JiaoTong University School of Medicine Department of Colorectal Surgery Sun Yat-sen University Cancer Center Department of Medical Oncology Cancer Hospital Chinese Academy of Medical Sciences Department of Medical Oncology The Second Hospital of Zhejiang University School of Medicine Department of Oncology The Second Affiliated Hospital of Xi'an Jiaotong University Department of Medical Oncology Nanjing Drum Tower Hospital Department of Medical Oncology The Sixth Affiliated Hospital of Sun Yat-sen University

The impact of maintenance therapy on progression-free survival and overall survival as well as quality of life of Chinese patients with metastatic colorectal cancer has long been under ***,some phase III clinical trials have revealed that maintenance therapy can significantly prolong the progression-free survival while maintain an acceptable safety *** on this evidence and common treatment practice in China,we now generated one Expert Consensus on Maintenance Treatment for Metastatic Colorectal Cancer in China to further specify the necessity of maintenance therapy,suitable candidates for such treatment,and appropriate regimens.

关键词： Metastatic colorectal cancer, Maintenance therapy, Consensus

STUDY ON ANALYTICAL PERFORMANCE OF LOW-POWERED ArMPT-AES

在线全文

学校读者我要写书评

暂无评论

Chinese Chemical Letters 1993年第10期4卷 917-920页

作者： Ying WANG xiang lin yuan Han Qi ZHANG Wen Jun YANG Qin Han JIN Department of Chemistry,Jilin University,Changchun,130023

In this paper the analytical performance of the low-powered Ar microwave plasma torch atomic emission spectrometry(MPT-AES) was *** experimental results indicate that the analytical performance of low-powered ArMPT-AE... 详细信息

关键词： STUDY ON ANALYTICAL PERFORMANCE OF LOW-POWERED ArMPT-AES HCI

The Chinese Society of Clinical Oncology(CSCO):clinical guidelines for the diagnosis and treatment of gastric cancer

在线全文

学校读者我要写书评

暂无评论

Cancer Communications 2019年第1期39卷 75-105页

作者： Feng-Hua Wang lin Shen Jin Li Zhi-Wei Zhou Han Liang Xiao-Tian Zhang Lei Tang Yan Xin Jing Jin Yu-Jing Zhang xiang-lin yuan Tian-Shu Liu Guo-Xin Li Qi Wu Hui-Mian Xu Jia-Fu Ji yuan-Fang Li Xin Wang Shan Yu Hao Liu Wen-Long Guan Rui-Hua Xu Department of Medical Oncology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhou 510060GuangdongP.R.China Department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Department of Gastrointestinal OncologyPeking University Cancer Hospital and InstituteBeijing 100142P.R.China Department of Oncology Shanghai East HospitalTongji University School of MedicineShanghai 200120P.R.China Department of Gastric Surgery Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhou 510060GuangdongP.R.China Department of Gastric Cancer Tianjin Medical University Cancer Institute&HospitalNational Clinical Research Center of CancerTianjin’s Clinical Research Cancer for CancerKey Laboratory of Cancer Prevention and TherapyTianjin 300060P.R.China Medical Imaging Department Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Department of Gastrointestinal OncologyPeking University Cancer Hospital and InstituteBeijing 100142P.R.China Pathology Laboratory of Gastrointestinal Tumor The First Hospital of China Medical UniversityShenyang 110001LiaoningP.R.China Department of Radiation Oncology National Cancer CenterChina and Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021P.R.China Department of Radiotherapy Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhou 510060GuangdongP.R.China Department of Medical Oncology Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and TechnologyWuhan 430030HubeiP.R.China Department of Medical Oncology Zhongshan Hospital Affiliated to Fudan UniversityShanghai 200032P.R.China Department of General Surgery Nanfang Hospital Affi

China is one of the countries with the highest incidence of gastric *** are differences in epidemiological characteristics,clinicopathological features,tumor biological characteristics,treatment patterns,and drug selection between gastric cancer patients from the Eastern and Western ***-Chinese guidelines cannot specifically reflect the diagnosis and treatment characteristics for the Chinese gastric cancer *** Chinese Society of Clinical Oncology(CSCO)arranged for a panel of senior experts specializing in all sub-specialties of gastric cancer to compile,discuss,and revise the guidelines on the diagnosis and treatment of gastric cancer based on the findings of evidence-based medicine in China and *** referring to the opinions of industry experts,taking into account of regional differences,giving full consideration to the accessibility of diagnosis and treatment resources,these experts have conducted experts’consensus judgement on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic *** guideline uses tables and is complemented by explanatory and descriptive notes covering the diagnosis,comprehensive treatment,and follow-up visits for gastric cancer.

关键词： Chinese Society of Clinical Oncology(CSCO) Gastric cancer Diagnosis Surgery Neoadjuvant Adjuvant Radiotherapy Chemotherapy Targeted therapy Immunotherapy

The Chinese Society of Clinical Oncology(CSCO):Clinical guidelines for the diagnosis and treatment of gastric cancer,2021

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2021年第8期41卷 747-795页

作者： Feng-Hua Wang Xiao-Tian Zhang yuan-Fang Li Lei Tang Xiu-Juan Qu Jie-Er Ying Jun Zhang ling-Yu Sun Rong-Bo lin Hong Qiu Chang Wang Miao-Zhen Qiu Mu-Yan Cai QiWu Hao Liu Wen-Long Guan Ai-Ping Zhou Yu-Jing Zhang Tian-Shu Liu Feng Bi xiang-lin yuan Sheng-xiang Rao Yan Xin Wei-Qi Sheng Hui-Mian Xu Guo-Xin Li Jia-Fu Ji Zhi-Wei Zhou Han Liang Yan-Qiao Zhang Jing Jin lin Shen Jin Li Rui-Hua Xu Department of Medical Oncology State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China Department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital and InstituteBeijing 100142P.R.China Department of Gastric Surgery State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China Department of Radiology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital and InstituteBeijing 100142P.R.China Department of Medical Oncology The First Hospital of China Medical UniversityShenyangLiaoning 110001P.R.China Department of Medical Oncology Zhejiang Cancer HospitalHangzhouZhejiang 310006P.R.China Department of Medical Oncology Ruijin HospitalShanghai Jiaotong University School of MedicineShanghai 200025P.R.China Department of Surgical Oncology The Fourth Affiliated Hospital of Harbin Medical UniversityHarbinHeilongjiang 150001P.R.China Department of Medical Oncology Fujian Cancer HospitalFuzhouFujian 350000P.R.China Department of Medical Oncology Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and TechnologyWuhanHubei 430030P.R.China Cancer Center of The First Hospital of Jilin University ChangchunJilin 130021P.R.China Department of Pathology State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center of Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China Department of Endoscopy Center Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital and InstituteBeijing 100142P.R.China Department of General Surgery Nanfang HospitalSouthern Medical UniversityGuangzhouGuan

There exist differences in the epidemiological characteristics,clinicopathological features,tumor biological characteristics,treatment patterns,and drug selections between gastric cancer patients from the Eastern and Western *** Chinese Society of Clinical Oncology(CSCO)has organized a panel of senior experts specializing in all sub-specialties of gastric cancer to compile a clinical guideline for the diagnosis and treatment of gastric cancer since 2016 and renews it *** into account regional differences,giving full consideration to the accessibility of diagnosis and treatment resources,these experts have conducted expert consensus judgment on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes in *** 2021 CSCO Clinical Practice Guidelines for Gastric Cancer covers the diagnosis,treatment,follow-up,and screening of gastric *** on the 2020 version of the CSCO Chinese Gastric Cancer guidelines,this updated guideline integrates the results ofmajor clinical studies from China and overseas for the past year,focused on the inclusion of research data from the Chinese population for more personalized and clinically relevant *** the comprehensive treatment of non-metastatic gastric cancer,attentions were paid to neoadjuvant *** value of perioperative chemotherapy is gradually becoming clearer and its recommendation level has been *** the comprehensive treatment of metastatic gastric cancer,recommendations for immunotherapy were included,and immune checkpoint inhibitors fromthird-line to the first-line of treatment for different patient groups with detailed notes are provided.

关键词： adjuvant chemotherapy Chinese Society of Clinical Oncology(CSCO) diagnosis gastric cancer immunotherapy neoadjuvant radiotherapy surgery targeted therapy

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2024年第1期44卷 127-172页

作者： Feng-Hua Wang Xiao-Tian Zhang Lei Tang Qi Wu Mu-Yan Cai yuan-Fang Li Xiu-Juan Qu Hong Qiu Yu-Jing Zhang Jie-Er Ying Jun Zhang ling-Yu Sun Rong-Bo lin Chang Wang Hao Liu Miao-Zhen Qiu Wen-Long Guan Sheng-xiang Rao Jia-Fu Ji Yan Xin Wei-Qi Sheng Hui-Mian Xu Zhi-Wei Zhou Ai-Ping Zhou Jing Jin xiang-lin yuan Feng Bi Tian-Shu Liu Han Liang Yan-Qiao Zhang Guo-Xin Li Jun Liang Bao-Rui Liu lin Shen Jin Li Rui-Hua Xu Department of Medical Oncology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongP.R.China Department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer HospitalBeijingP.R.China Department of Radiology Peking University Cancer HospitalBeijingP.R.China Department of Endoscopy Center Peking University Cancer HospitalBeijingP.R.China Department of Pathology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center of Cancer MedicineGuangzhouGuangdongP.R.China Department of Gastric Surgery Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongP.R.China Department of Medical Oncology The First Hospital of China Medical UniversityShenyangLiaoningP.R.China Department of Medical Oncology Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and TechnologyWuhanHubeiP.R.China Department of Radiotherapy Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongP.R.China Department of Medical Oncology Zhejiang Cancer HospitalHangzhouZhejiangP.R.China Department of Medical Oncology Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiP.R.China Department of Surgical Oncology The Fourth Affiliated Hospital of Harbin Medical UniversityHarbinHeilongjiangP.R.China Department of Medical Oncology Fujian Cancer HospitalFuzhouFujianP.R.China Tumor Center The First Hospital of Jilin UniversityChangchunJilinP.R.China Department of General Surgery Nanfang HospitalSouthern Medical UniversityGuangzhouGuangdongP.R.China Department of Radiology Zhongshan HospitalFudan UniversityShanghaiP.R.China Department of

The 2023 update of the Chinese Society of Clinical Oncology(CSCO)Clini-cal Guidelines for Gastric Cancer focuses on standardizing cancer diagnosis and treatment in China,reflecting the latest advancements in evidence-based medicine,healthcare resource availability,and precision *** updates address the differences in epidemiological characteristics,clinicopatho-logical features,tumor biology,treatment patterns,and drug selections between Eastern and Western gastric cancer *** revisions include a structured template for imaging diagnosis reports,updated standards for molecular marker testing in pathological diagnosis,and an elevated recommendation for neoadju-vant chemotherapy in stage III gastric *** advanced metastatic gastric cancer,the guidelines introduce new recommendations for immunotherapy,anti-angiogenic therapy and targeted drugs,along with updated management strategies for human epidermal growth factor receptor 2(HER2)-positive and deficient DNA mismatch repair(dMMR)/microsatellite instability-high(MSI-H)***,the guidelines offer detailed screening recommendations for hereditary gastric cancer and an appendix listing drug treatment regimens for various stages of gastric *** 2023 CSCO Clinical Guidelines for Gastric Cancer updates are based on both Chinese and international clinical research and expert consensus to enhance their applicability and relevance in clinical practice,particularly in the heterogeneous healthcare landscape of China,while maintaining a commitment to scientific rigor,impartiality,and timely revisions.

关键词： Chinese Society of Clinical Oncology(CSCO) gastric cancer diagnosis surgery neoadjuvant adjuvant radiotherapy chemotherapy targeted therapy immunotherapy